Understanding how pancreatic cancer becomes resistant to chemotherapy
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
This study is looking into why pancreatic cancer sometimes stops responding to chemotherapy and aims to find new ways to make treatments work better for patients like you by understanding how cancer cells change and interact with their surroundings.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10926946 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind why pancreatic cancer often stops responding to chemotherapy over time. It focuses on the metabolic changes in cancer cells and their interactions with the surrounding environment, which may contribute to this resistance. By studying patient-derived models, the research aims to identify specific genes and pathways that could be targeted to improve treatment outcomes. The ultimate goal is to develop new therapies or combinations that enhance the effectiveness of existing treatments for pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are undergoing or have undergone chemotherapy.
Not a fit: Patients with pancreatic cancer who are not receiving chemotherapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and increased survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in targeting metabolic vulnerabilities in cancer, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.